Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
RATIONALE: Pentostatin may be effective in treating chronic graft-versus-host disease by stopping the immune system from rejecting donor stem cells or donor white blood cells.
PURPOSE: This phase II trial is studying how well pentostatin works in treating patients with chronic graft-versus-host disease that is refractory (not responsive) to treatment with steroids.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
OBJECTIVES:
Primary
- Determine the response rate in patients with refractory chronic graft-versus-host disease treated with pentostatin.
Secondary
- Determine the time to next immunosuppressive agent (i.e., the time to progression from best response) in patients treated with this drug.
- Determine the toxicity of this drug in these patients.
- Determine the infection rate in patients treated with this drug.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the changes in lymphocyte populations in patients treated with this drug.
- Determine the survival of patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive pentostatin IV over 20-30 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Patients who achieve a complete response after 6 courses receive 4 additional courses. Patients who achieve a partial response, minor response, or stable disease after 6 courses may receive up to 6 additional courses.
Patients are followed every 4 weeks for 1 year, every 3 months for 2 years, and then annually for 5 years.
PROJECTED ACCRUAL: Approximately 37 patients will be accrued for this study.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Delaware
-
Lewes, Delaware, Yhdysvallat, 19958
- Tunnell Cancer Center at Beebe Medical Center
-
Newark, Delaware, Yhdysvallat, 19713
- CCOP - Christiana Care Health Services
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60637-1470
- University of Chicago Cancer Research Center
-
Chicago, Illinois, Yhdysvallat, 60612-7243
- University of Illinois Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21201
- Greenebaum Cancer Center at University of Maryland Medical Center
-
Elkton, Maryland, Yhdysvallat, 21921
- Union Hospital Cancer Program at Union Hospital
-
-
Minnesota
-
Rochester, Minnesota, Yhdysvallat, 55905
- Mayo Clinic Cancer Center
-
-
New Jersey
-
Voorhees, New Jersey, Yhdysvallat, 08043
- Cancer Institute of New Jersey at Cooper - Voorhees
-
-
New York
-
New York, New York, Yhdysvallat, 10021
- New York Weill Cornell Cancer Center at Cornell University
-
-
North Carolina
-
Durham, North Carolina, Yhdysvallat, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Yhdysvallat, 27157-1096
- Wake Forest University Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, Yhdysvallat, 43210-1240
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19111-2497
- Fox Chase Cancer Center - Philadelphia
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15224-1791
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
-
-
Virginia
-
Richmond, Virginia, Yhdysvallat, 23298-0037
- Virginia Commonwealth University Massey Cancer Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
- Histologic documentation of chronic GvHD following allogeneic HCT or donor lymphocyte infusion.
- Patients may have progressive, quiescent, or de novo onset chronic GvHD.
Patients with extensive stage chronic GvHD requiring systemic immunosuppressive therapy are eligible. Patients with limited stage disease are excluded. Extensive stage is defined according to Seattle criteria (9) as either:
- Generalized skin involvement or
Limited skin involvement or hepatic involvement with any one of the following:
- Liver histology showing chronic progressive hepatitis, bridging necrosis or cirrhosis
- Eye involvement (Schirmer's test with < 5 mm wetting)
- Involvement of minor salivary glands or oral mucosa
- Involvement of any other organ
Patients must have failed treatment with, or experience progression after, prior corticosteroids for extensive stage chronic GvHD, as defined below.
4.1 Patients will be considered to have failed corticosteroids if they have any one of the following criteria:
- Progressive disease or less than a minor response in any organ system despite 2 weeks on corticosteroid treatment at least 1 mg/kg methylprednisolone or equivalent.
- Failure to achieve at least a minor response after at least 4 weeks of treatment with a dose of ≥ 0.5 mg/kg methylprednisolone or equivalent.
- Achievement of less than a partial response at 8 weeks of corticosteroid treatment despite use of a dose ≥ 0.5 mg/kg methylprednisolone or equivalent.
- Requirement of ≥ 0.5 mg/kg methylprednisolone or equivalent to maintain a partial response or better at 12 weeks of corticosteroid treatment.
- Requirement of > 10 mg/kg methylprednisolone or equivalent to maintain a partial response or better at 18 weeks of corticosteroid treatment.
4.2 Patients with progression of extensive stage chronic GvHD after a prior history of treatment with at least 18 weeks of corticosteroids, now requiring the reintroduction of corticosteroids (> 10 mg/day methylprednisolone or equivalent) or an additional agent (including photopheresis, PUVA) for treatment.
- Patients with established chronic GvHD not improving or progressing on other immunosuppressive agents are also eligible if steroid refractoriness has been established previously.
- Age ≥ 18 years
- Performance Status 0-3
- Patients on mechanical ventilation are excluded.
- No active infection. Patients with active infection requiring antibiotic therapy are not eligible until infection is controlled.
- No HIV infection. Patients with HIV infection are excluded because of safety concerns in this patient population.
- Non-pregnant and non-nursing. Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial (although it is unlikely that successful pregnancy will occur in patients with chronic GvHD). Appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (Norplant®), or double barrier method (diaphragm plus condom).
Required Initial Laboratory Values:
- Calc. Creatinine Clearance ≥ 30 mL/min/1.73 m^2
- ANC > 1000/μL
- Platelets > 50,000/μL without transfusion
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Pentostatin
treatment of pts with refractory graft vs host disease
|
4 mg/sq m IV infusion over 20-30 min q 2 weeks
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Response Rate
Aikaikkuna: 3 months
|
Percentage of participants who had a complete or partial response defined by the Hopkins scoring system. A complete response is defined as the disappearance of signs and symptoms of chronic GVHD in all involved systems that is sustained for at lest 4 weeks. A partial response is an improvement by 2 or more points in at least one system score, which is sustained for at least 4 weeks, with no signs of worsening in others. |
3 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Grade 3 or Higher Non-hematologic Adverse Events
Aikaikkuna: Duration of treatment (up to 5 years)
|
Number of participants experiencing a grade 3, 4 or 5 clinically significant non-hematologic adverse events, at least possibly related to treatment.
|
Duration of treatment (up to 5 years)
|
|
Overall Survival At 1 Year
Aikaikkuna: 1 year
|
Percentage of patients who were alive at 1 year.
|
1 year
|
|
Overall Survival At 2 Years
Aikaikkuna: 2 year
|
Percentage of patients who were alive at 2 years.
|
2 year
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Pharmacokinetics Association Between Exposure and Response At 3 Months
Aikaikkuna: 3 months
|
The individual PK parameters will be derived by using a noncompartmental analysis of the plasma-concentration-time data
|
3 months
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Opintojen puheenjohtaja: Sherif S. Farag, MD, PhD, Ohio State University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- CALGB-100101
- U10CA031946 (Yhdysvaltain NIH-apuraha/sopimus)
- CDR0000341678 (Rekisterin tunniste: NCI Physician Data Query)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .